The Filing Desk

CytoSorbents

CTSO · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CTSO · Last close · November 19, 2026
$5.13
Value CytoSorbents yourself

CytoSorbents' revenue rose 4.1% to $37 million in fiscal 2025. Its operating margin was −39.8%, up from −46.2% a year earlier. Free cash flow was −$13 million. The diluted share count rose 14.3%.

CYTOSORBENTS CORPORATION Latest fiscal year ended December 31, 2025 10-K filed March 30, 2026 · 0001104659-26-036451 Updated
Revenue
$37M
4.1%
Operating margin
−39.8%
6.4 pts
Net income
−$8M
 
Free cash flow
−$13M
 
Return on equity
−96.4%
23.4 pts
Market cap
$16M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What CytoSorbents does

CytoSorbents makes blood-cleaning devices for hospitals. Its cartridges are filled with tiny porous plastic beads that soak up harmful substances from a patient's blood as it is pumped outside the body through machines hospitals already use, such as dialysis machines and heart-lung machines used in surgery. Doctors use them to remove blood thinners during heart surgery, to lower the risk of severe bleeding, and to remove substances that cause dangerous inflammation in illnesses such as sepsis, burns and liver failure.

Its main product, CytoSorb, is approved in the European Union and sold in more than 70 countries, with more than 300,000 devices used to date; Germany is its biggest market. CytoSorb is not approved in the United States. The company sells through its own sales teams in parts of Europe and through partners and distributors elsewhere. It also sells a cartridge used to treat donor organs before transplant, a version for animals called VetResQ, and a blood pump called PuriFi in some countries.

In the US and Canada it is seeking approval for DrugSorb-ATR, a similar device meant to reduce bleeding in heart bypass patients taking blood thinners. The FDA has given it two Breakthrough Device designations, meant to speed up its review, but it is not yet approved. The company is based in Princeton, New Jersey.

Its biggest risks, as it describes them

  • A history of losses and a possible need to raise more money to keep operating.
  • The FDA and Health Canada may not approve DrugSorb-ATR, its planned product for North America.
  • Losing its European approval, without which it could not sell CytoSorb there.
  • Its reliance on Germany, its main market, and on many different distributors elsewhere.
  • Hospitals may not get paid enough by insurers and health systems to use its products.
From CytoSorbents's annual report on Form 10-K, filed March 30, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

CytoSorbents lost money in fiscal 2025: a net loss of $8 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments52221436
Debt incl. finance leases055—17
Net debt (negative means net cash)−52−17−9—10
Net debt to EBITDA—————
Debt to equity0.0x0.1x0.2x—2.8x
Interest coverage——−84.8x−12.8x−7.1x
Current ratio4.7x3.5x1.8x2.2x2.1x
Quick ratio4.3x3.1x1.6x1.9x1.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project CytoSorbents' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $269,332 of CytoSorbents shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 15, 2026Phillip P. ChanChief Executive Officer, DirectorBought3,774$6.00$22,644Form 4
Sep 15, 2026Alan D. SobelDirectorBought2,500$6.10$15,254Form 4
Sep 14, 2026Vincent CapponiPresident and COOBought2,073$6.05$12,537Form 4
Sep 4, 2026Phillip P. ChanChief Executive Officer, DirectorBought200,000$0.35$70,000Form 4
Jun 15, 2026Peter J MarianiChief Financial OfficerBought100,000$0.44$44,000Form 4
Jun 15, 2026Phillip P. ChanChief Executive Officer, DirectorBought10,333$0.43$4,443Form 4
Jun 12, 2026Phillip P. ChanChief Executive Officer, DirectorBought251,136$0.40$100,454Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 9——
Rule of 40−81.8%−26.8%−29.7%
Altman Z''−19.25−21.30−23.50
Accruals ratio−13.1%−12.5%9.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsFail——
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rosePassFailPass
Revenue rose relative to assetsPassPassPass
F-score3 of 9——
Companies that report no gross profit are scored on the other eight.

Compare

Put CytoSorbents side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CytoSorbentsFY254.1%−39.8%−33.8%———
ClearPoint NeuroFY2517.8%−65.4%−66.1%−104.7%—4Compare
Utah Medical ProductsFY25−5.8%29.6%37.2%26.8%−6.0x6Compare
SenseonicsFY2556.9%−193.8%−170.9%——4Compare
PulsenmoreFY25314.3%—−82.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue10152225414335313637
Revenue growth98.8%59.0%48.5%10.9%64.3%5.3%−19.6%−10.4%14.5%4.1%
Gross profit6101518303221222526
Research and development438129161516——
Operating income−12−10−16−19−10−23−32−32−16−15
Net income−12−8−17−19−8−25−33−29−21−8
Diluted EPS (US$)−0.46−0.32−0.56−0.60−0.20−0.57−0.75−0.65−0.38−0.13
Diluted shares (millions)25283132394344455462
Cash flow
Cash from operations−7−6−11−17−6−14−28−22−14−12
Capital expenditure0111146000
Free cash flow−7−7−12−17−6−18−34−22−15−13
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation3342443443
Balance sheet at fiscal year end
Cash and short-term investments51722127152221436
Debt incl. finance leases51010150055—17
Total assets10243427909063534744
Total liabilities8141724112728303638
Shareholders' equity11017379633524116
Margins and ratios
Gross margin58.5%63.6%66.7%70.5%73.0%74.4%59.8%70.6%69.9%71.5%
Operating margin−120.6%−65.0%−69.2%−76.0%−25.3%−52.7%−90.9%−102.8%−46.2%−39.8%
Net margin−123.5%−55.8%−76.5%−77.2%−19.1%−56.9%−94.6%−94.1%−58.2%−22.1%
Free cash flow margin−72.1%−49.2%−51.1%−70.0%−15.4%−40.9%−98.9%−71.4%−41.3%−33.8%
Rule of 40 (growth + FCF margin)26.7%9.8%−2.6%−59.1%48.9%−35.6%−118.6%−81.8%−26.8%−29.7%
Return on capital−543.4%−395.0%−331.0%−279.0%−116.8%−197.1%−173.7%−154.7%——
Return on equity−210.4%−145.9%−126.6%−189.3%−19.0%−34.6%−67.0%−99.4%−119.8%−96.4%
Return on assets−112.3%−50.1%−59.0%−62.6%−13.4%−27.4%−43.0%−50.3%−41.3%−17.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: CytoSorbents' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with CytoSorbents.